Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
October 16, 2013
NANTES, France Laboratoire Lescuyer successfully obtained a positive opinion on a health claim under Article 14 for a food supplement Limicol from the European Food Safety Authority (EFSA) Nutrition, Dietetic product and Allergies (NDA) panel.
With support from contract research company Biofortis, the product has five years of research and three clinical trials to scientifically back its benefits in reducing LDL cholesterol. According to Biofortis, only 16 Article 14 health claims had previously received a positive opinion from EFSA for adult nutritional products in Europe, and the first time a food supplement dossier with data protection received a positive assessment from EFSA regarding a disease risk reduction claim.
We are confident that this success will motivate new players in targeting EFSA claims with a new and proven methodology," said Murielle Cazaubiel, head of Biofortis Clinical.
You May Also Like
Here's why creatine sales are surging this past yearFeb 21, 2024
DSHEA's 25th anniversary: Industry vets, critics respondFeb 21, 2024
The Month in 2: Sports – videoFeb 21, 2024
Tianeptine sales spur another FDA warning, action by state lawmakersFeb 20, 2024